Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia.

× No keyword cloud information.

14 in total

1. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.

Authors: R Hehlmann; H Ansari; J Hasford; H Heimpel; D K Hossfeld; H J Kolb; H Löffler; H Pralle; W Queisser; A Reiter; A Hochhaus
Journal: Br J Haematol Date: 1997-04 Impact factor: 6.998

2. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors: M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal: Science Date: 2001-06-21 Impact factor: 47.728

3. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

Authors: Nikolas von Bubnoff; Folker Schneller; Christian Peschel; Justus Duyster
Journal: Lancet Date: 2002-02-09 Impact factor: 79.321

4. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Authors: Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Fausto Castagnetti; Gianantonio Rosti; Costanza Bosi; Stefania Paolini; Michela Rondoni; Pier Paolo Piccaluga; Francesca Palandri; Panagiota Giannoulia; Giulia Marzocchi; Simona Luatti; Nicoletta Testoni; Ilaria Iacobucci; Daniela Cilloni; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal: Haematologica Date: 2007-03 Impact factor: 9.941

5. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Authors: Martin C Müller; Jorge E Cortes; Dong-Wook Kim; Brian J Druker; Philipp Erben; Ricardo Pasquini; Susan Branford; Timothy P Hughes; Jerald P Radich; Lynn Ploughman; Jaydip Mukhopadhyay; Andreas Hochhaus
Journal: Blood Date: 2009-09-24 Impact factor: 22.113

6. Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors: J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal: Blood Date: 1984-04 Impact factor: 22.113

7. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Authors: A Hochhaus; S Kreil; A S Corbin; P La Rosée; M C Müller; T Lahaye; B Hanfstein; C Schoch; N C P Cross; U Berger; H Gschaidmeier; B J Druker; R Hehlmann
Journal: Leukemia Date: 2002-11 Impact factor: 11.528

8. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Authors: Thomas Ernst; Franz X Gruber; Oliver Pelz-Ackermann; Jacqueline Maier; Markus Pfirrmann; Martin C Müller; Ingvild Mikkola; Kimmo Porkka; Dietger Niederwieser; Andreas Hochhaus; Thoralf Lange
Journal: Haematologica Date: 2009-07-16 Impact factor: 9.941

9. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

Authors: Wendy T Parker; Musei Ho; Hamish S Scott; Timothy P Hughes; Susan Branford
Journal: Blood Date: 2011-12-30 Impact factor: 22.113

10. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Authors: Timothy Hughes; Giuseppe Saglio; Susan Branford; Simona Soverini; Dong-Wook Kim; Martin C Müller; Giovanni Martinelli; Jorge Cortes; Lan Beppu; Enrico Gottardi; Dongho Kim; Philipp Erben; Yaping Shou; Ariful Haque; Neil Gallagher; Jerald Radich; Andreas Hochhaus
Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544